Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan + Cetuximab in HER2-low Metastatic Colorectal Cancer
NCT07691489Phase 2Not yet recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in colorectal cancer (CRC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07691489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691489.